Trial reportLasers in medical science2025
The effects of intravenous laser irradiation of blood with red and blue light on stroke risk biomarkers and neurological function: a double blind randomized controlled trial.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of photobiomodulation in post-stroke dysfunctions: a literature review of recent clinical studies.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to compare the effects of red- and blue-light intravascular laser irradiation of blood (ILIB) on stroke-related biomarkers and neurological recovery in post-stroke patients. In this double-blind, randomized, case-crossover trial, 30 patients within 6 months post-stroke received 10 sessions each of red-light and blue-light ILIB in randomized order with a two-month washout. Outcomes included blood count, biochemical markers (glucose, coagulation, inflammation), and neurological assessments (Fugl-Meyer Upper Limb, Berg Balance Scale, Mini-Mental State Examination). Paired t-tests and two-way ANOVA were applied. Red-light (650 nm) ILIB reduced RBC count (− 0.08 × 10^6/µL; 95% CI − 0.16 to − 0.002) and fibrinogen (− 27.6 mg/dL; 95% CI − 50.27 to − 4.93) versus baseline, and further decreased RBC (− 0.13 × 10^6/µL; 95% CI − 0.26 to − 0.02) and hematocrit (− 1.12%; 95% CI − 2.48 to − 0.14) compared with blue-light (415 nm) ILIB. Age-stratified analysis showed that in older adults, red-light ILIB reduced erythrocyte indices (RBC − 0.14 × 10⁶/µL, Hb − 0.43 g/dL, Hct − 1.31%), while in younger participants, red-light ILIB lowered inflammatory markers (IL-6 − 1.91 pg/mL, fibrinogen − 29.6 mg/dL). For neurological function, both red-light and blue-light ILIB improved motor and balance performance without significant between-group differences. In age-stratified analysis, blue-light ILIB improved motor function in both age groups (FMA-UE: old + 2.80, young + 4.27) and enhanced balance (BBS: old + 4.33, young + 4.47), whereas red-light ILIB further improved upper-limb function in older adults (FMA-UE + 2.13) and cognition in younger participants (MMSE + 1.93). ILIB at different wavelengths may differentially influence hematologic and inflammatory biomarkers associated with stroke risk and functional recovery. These findings warrant further investigation in larger and longer-term studies.
Indexed as
Identifiers
41423539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.